10x Genomics Management

Management criteria checks 2/4

10x Genomics' CEO is Serge Saxonov, appointed in Jul 2012, has a tenure of 11.67 years. total yearly compensation is $18.81M, comprised of 2.7% salary and 97.3% bonuses, including company stock and options. directly owns 3.37% of the company’s shares, worth $145.66M. The average tenure of the management team and the board of directors is 6 years and 6.6 years respectively.

Key information

Serge Saxonov

Chief executive officer

US$18.8m

Total compensation

CEO salary percentage2.7%
CEO tenure11.7yrs
CEO ownership3.4%
Management average tenure6yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics cut to Sell at Goldman Sachs on slower sales ramp

Aug 18

10x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling

Jul 30

10x Genomics guides to Q2 revenues below consensus; shares down 13% after hours

Jul 14

CEO Compensation Analysis

How has Serge Saxonov's remuneration changed compared to 10x Genomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Compensation vs Market: Serge's total compensation ($USD18.81M) is above average for companies of similar size in the US market ($USD6.32M).

Compensation vs Earnings: Serge's compensation has increased whilst the company is unprofitable.


CEO

Serge Saxonov (46 yo)

11.7yrs

Tenure

US$18,805,294

Compensation

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...


Leadership Team

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder11.7yrsUS$18.81m3.37%
$ 145.7m
Benjamin Hindson
Co-Founder11.7yrsUS$9.87m2.71%
$ 117.3m
Justin McAnear
Chief Financial Officer5.4yrsUS$6.84m0.050%
$ 2.2m
Eric Whitaker
Chief Legal Officer6.7yrsUS$11.90m0.099%
$ 4.3m
Michael Schnall-Levin
Founding Scientist & CTO2.2yrsno datano data
Cassie Corneau
Manager of Investor Relations and Strategic Financeno datano datano data
Rebecca Port
Chief People Officer3.2yrsno datano data
James Bryant
Director of Legalno datano datano data
Nikhil Rao
Director of Product Managementno datano datano data
Florian Baumgartner
Senior Product Managerno datano datano data
Courtney Anderson
Sr. Product Marketing Managerno datano datano data
Anushka Brownley
Senior Product Manager of Informaticsno datano datano data

6.0yrs

Average Tenure

47.5yo

Average Age

Experienced Management: TXG's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Serge Saxonov
Co-Founder11.7yrsUS$18.81m3.37%
$ 145.7m
Benjamin Hindson
Co-Founder11.7yrsUS$9.87m2.71%
$ 117.3m
Kimberly Popovits
Independent Director4yrsUS$265.76k0.0023%
$ 99.5k
John Stuelpnagel
Independent Chairman10.6yrsUS$329.99k2.05%
$ 88.6m
Shehnaaz Suliman
Independent Director4.6yrsUS$268.26k0.0023%
$ 99.5k
Mathai Mammen
Independent Director6.6yrsUS$263.26k0.14%
$ 6.2m
Sridhar Kosaraju
Independent Director4.9yrsUS$278.26k0.028%
$ 1.2m

6.6yrs

Average Tenure

50yo

Average Age

Experienced Board: TXG's board of directors are considered experienced (6.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.